Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Pfeffer, Marc A., Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C., Køber, Lars V., Lawson, Francesca C., Ping, Lin, Wei, Xiaodan, Lewis, Eldrin F., Maggioni, Aldo P., McMurray, John J.V., Probstfield, Jeffrey L., Riddle, Matthew C., Solomon, Scott D., Tardif, Jean-Claude·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1509225

Cited by (1,016)

Items 201–300 of 1,016

  1. Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease
    Mark O. Goodarzi, Jerome I. Rotter · 2020 · Circulation Research
  2. Therapeutic Advances in Diabetic Nephropathy
    Hanny Sawaf, George Thomas, Jonathan J. Taliercio, Georges Nakhoul, Tushar J. Vachharajani, Ali Mehdi · 2022 · Journal of Clinical Medicine
  3. Diabetic cardiomyopathy
    Matthew M.Y. Lee, John J.V. McMurray, Ana Lorenzo-Almorós, Søren Lund Kristensen, Naveed A. Sattar, Pardeep S. Jhund, Mark Colquhoun Petrie · 2018 · Heart
  4. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
    Azoulay, Laurent, Filion, Kristian B, Platt, Robert W, Dahl, Matthew, Dormuth, Colin R, Clemens, Kristin K, Durand, Madeleine, Juurlink, David N, Targownik, Laura E, Turin, Tanvir C et al. · 2016 · BMJ
  5. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
    Azoulay, Laurent, Filion, Kristian B., Platt, Robert W., Dahl, Matthew, Dormuth, Colin R., Clemens, Kristin K., Durand, Madeleine, Hu, Nianping, Juurlink, David N., Paterson, J. Michael et al. · 2016 · JAMA Internal Medicine
  6. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure
    Marso, Steven P., Baeres, Florian M.M., Bain, Stephen C., Goldman, Bryan, Husain, Mansoor, Nauck, Michael A., Poulter, Neil R., Pratley, Richard E., Thomsen, Anne Bloch, Buse, John B. · 2020 · Journal of the American College of Cardiology
  7. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
    Robert A. Scott, Daniel F. Freitag, Li Li, Audrey Y. Chu, Praveen Surendran, Robin Young, Niels Grarup, Alena Stančáková, Yuning Chen, Tibor V. Varga et al. · 2016 · Science Translational Medicine
  8. Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus
    Emil Wolsk, Brian Lee Claggett, Marc Alan Pfeffer, Rafael Díaz, Kenneth Dickstein, Hertzel C. Gerstein, Francesca C. Lawson, Eldrin Foster Lewis, Aldo Pietro Maggioni, John J.V. McMurray et al. · 2017 · Journal of the American Heart Association
  9. Diabetes in Older People
    Graydon S. Meneilly, Aileen Knip, David B. Miller, Diana Sherifali, Daniel Tessier, Afshan Zahedi · 2018 · Canadian Journal of Diabetes
  10. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
    Giuseppe Patti, Ilaria Cavallari, Felicita Andreotti, Paolo Calabrò, Plinio Lorenzo Cirillo, Gentian Denas, Mattía Galli, Enrica Golia, Ernesto Maddaloni, Rossella Marcucci et al. · 2018 · Nature Reviews Cardiology
  11. Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
    Pierret, Aureliane C. S., Mizuno, Yuya, Saunders, Pippa, Lim, Eshaya, De Giorgi, Riccardo, Howes, Oliver D., McCutcheon, Robert A., McGowan, Barbara, Sen Gupta, Piya, Smith, Daniel et al. · 2025 · JAMA Psychiatry
  12. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
    Mechanick, Jeffrey I., Farkouh, Michael E., Newman, Jonathan D., Garvey, W. Timothy · 2020 · Journal of the American College of Cardiology
  13. Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
    George Jia, Hetty Bai, Bethany Mather, Michael A. Hill, Guanghong Jia, James R. Sowers · 2024 · International Journal of Molecular Sciences
  14. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
    Singh, Awadhesh Kumar, Singh, Ritu · 2020 · Diabetes & Metabolic Syndrome: Clinical Research & Reviews
  15. The pharmacological management of metabolic syndrome
    Julie Rask Larsen, Lorena Dima, Christoph Ulrich Correll, Peter Manu · 2018 · Expert Review of Clinical Pharmacology
  16. Diabetes and Cardiovascular Disease: an Update
    Almourani, Rajaa, Chinnakotla, Bhavana, Patel, Richa, Kurukulasuriya, L. Romayne, Sowers, James · 2019 · Current Diabetes Reports
  17. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
    Tonneijck, Lennart, Smits, Mark M., Muskiet, Marcel H.A., Hoekstra, Trynke, Kramer, Mark H.H., Danser, A.H. Jan, ter Wee, Piet M., Diamant, Michaela, Joles, Jaap A., van Raalte, Daniël H. · 2016 · Diabetes Care
  18. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
    James R. Thrasher · 2017 · The American Journal of Cardiology
  19. GLP-1 receptor agonists and cardiovascular outcome trials: An update
    Eirini Andrikou, Costas P. Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios M. Tousoulis, Νικόλαος Παπάνας · 2018 · Hellenic Journal of Cardiology
  20. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
    Matthew James O’Brien, Susan Karam, Amisha Wallia, Raymond H. Kang, Andrew Cooper, Nicola Lancki, Margaret R. Moran, David T. Liss, Theodore A. Prospect, Ronald T. Ackermann · 2018 · JAMA Network Open
  21. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
    Binayak Sinha, Samit Ghosal · 2019 · Diabetes Research and Clinical Practice
  22. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
    Tanya Wilcox, Christophe E.M. De Block, Arthur Z. Schwartzbard, Jonathan D. Newman · 2020 · Journal of the American College of Cardiology
  23. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
    James R. Thrasher · 2017 · The American Journal of Medicine
  24. Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
    Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Geir Jenssen · 2020 · Transplant International
  25. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang, Zhengyuan Xia · 2021 · Cardiovascular Diabetology
  26. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
    Michael Albrecht Nauck, Daniel Robert Quast · 2021 · Frontiers in Endocrinology
  27. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
    Doyle-Delgado, Kacie, Chamberlain, James J., Shubrook, Jay H., Skolnik, Neil, Trujillo, Jennifer · 2020 · Annals of Internal Medicine
  28. Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis
    Paul MacDaragh Ryan, Sean Seltzer, Nathaniel Edward Hayward, David Avelar Rodriguez, Ryan Taylor Sless, Colin P. Hawkes · 2021 · The Journal of Pediatrics
  29. Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials
    Silverii, Giovanni Antonio, Monami, Matteo, Gallo, Marco, Ragni, Alberto, Prattichizzo, Francesco, Renzelli, Valerio, Ceriello, Antonio, Mannucci, Edoardo · 2024 · Diabetes Obesity and Metabolism
  30. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus
    Abhinav Sharma, Neha Jadeja Pagidipati, Robert M. Califf, Darren K. McGuire, Jennifer B. Green, Dave DeMets, Jyothis Thomas George, Hertzel C. Gerstein, Todd M. Hobbs, Rury R. Holman et al. · 2020 · Circulation
  31. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Hung, Chi-Sheng, Chen, Wen-Jone · 2021 · Diabetologia
  32. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
    Brady Park, Ehab Bakbak, Hwee Teoh, Aishwarya Krishnaraj, Fallon Dennis, Adrian Quan, Ori David Rotstein, Javed Butler, David A. Hess, Subodh Verma · 2024 · American Journal of Physiology-Heart and Circulatory Physiology
  33. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
    Levin, Philip A, Nguyen, Hiep, Wittbrodt, Eric, Kim, Seoyoung C. · 2017 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  34. New pharmacological strategies for protecting kidney function in type 2 diabetes
    Marcel H.A. Muskiet, David Collins. Wheeler, Hiddo J.L. Heerspink · 2018 · The Lancet Diabetes & Endocrinology
  35. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
    Heuvelman, Valerie D, Van Raalte, Daniël H, Smits, Mark M · 2020 · Cardiovascular Research
  36. Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
    Tang, Huilin, Shao, Hui, Shaaban, C. Elizabeth, Yang, Keming, Brown, Joshua, Anton, Stephen, Wu, Yonghui, Bress, Adam, Donahoo, William T., DeKosky, Steven T. et al. · 2023 · Journal of the American Geriatrics Society
  37. Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
    Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association · 2021 · Cardiology Discovery
  38. Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis
    Chiang, Cho-Hung, Jaroenlapnopparat, Aunchalee, Colak, Sena Cakir, Yu, Chun-Chiao, Xanthavanij, Nutchapon, Wang, Tsu-Hsien, See, Xin Ya, Lo, Shao-Wei, Ko, Albert, Chang, Yu-Cheng et al. · 2025 · Gastroenterology
  39. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
    Merlin C. Thomas · 2017 · Diabetes & Metabolism
  40. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Kelvin Tran, Young In Park, Shalin Pandya, Navin John Muliyil, Brandon David Jensen, Kovin Huynh, Quang Phuong Huynh Nguyen · 2017 · PubMed Central
  41. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012–2018
    Clemens Engler, Marco Leo, Bernhard Erich Pfeifer, Martin Juchum, Di Chen-Koenig, Karin Pölzl, Hans Schoenherr, David Vill, Juliana Oberdanner, Egon Eisendle et al. · 2020 · BMJ Open Diabetes Research & Care
  42. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
    Xie, Yan, Bowe, Benjamin, Xian, Hong, Loux, Travis, McGill, Janet B, Al-Aly, Ziyad · 2023 · The Lancet Diabetes & Endocrinology
  43. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
    Patorno, Elisabetta, Htoo, Phyo T., Glynn, Robert J., Schneeweiss, Sebastian, Wexler, Deborah J., Pawar, Ajinkya, Bessette, Lily G., Chin, Kristyn, Everett, Brendan M., Kim, Seoyoung C. · 2021 · Annals of Internal Medicine
  44. Heart Failure Outcomes in Clinical Trials of Glucose-Lowering Agents in Patients with Diabetes
    DAVID H. FITCHETT, Jacob Allen Udell, Silvio E. Inzucchi · 2016 · European Journal of Heart Failure
  45. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
    Francesco Paneni, Thomas Felix Lüscher · 2017 · The American Journal of Medicine
  46. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits
    Nauck, Michael A, Tuttle, Katherine R, Tschöp, Matthias H, Blüher, Matthias · 2026 · The Lancet
  47. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
    Mattía Galli, Stefano Benenati, Claudio Laudani, Beatrice Simeone, Gianmarco Sarto, Luis Ortega‐Paz, Erica Rocco, Marco Bernardi, Luigi Spadafora, Domenico D’Amario et al. · 2025 · Journal of the American College of Cardiology
  48. GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
    Wilbon, Sydney S., Kolonin, Mikhail G. · 2023 · Cells
  49. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
    Antonio Ceriello, Doina Catrinoiu, Chanchal Chandramouli, Francesco Cosentino, Annique C. Dombrowsky, Baruch Itzhak, Nebojsa M. Lalic, Francesco Prattichizzo, Oliver Schnell, Petar M Seferovic et al. · 2021 · Cardiovascular Diabetology
  50. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
    Stephen Charles Bain, Ofri Mosenzon, Rosario Arechavaleta, Paweł Bogdański, Abdurrahman Çömlekçi, Agostino Consoli, Chaicharn Deerochanawong, Kathleen Marie Dungan, María Cristina Faingold, Michael E. Farkouh et al. · 2018 · Diabetes Obesity and Metabolism
  51. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials
    Cao, Chuqing, Yang, Shuting, Zhou, Zhiguang · 2019 · Endocrine
  52. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor
    Helmstädter, Johanna, Keppeler, Karin, Küster, Leonie, Münzel, Thomas, Daiber, Andreas, Steven, Sebastian · 2022 · British Journal of Pharmacology
  53. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial
    Fudim, Marat, White, Jennifer, Pagidipati, Neha J., Lokhnygina, Yuliya, Wainstein, Julio, Murin, Jan, Iqbal, Nayyar, Öhman, Peter, Lopes, Renato D., Reicher, Barry et al. · 2019 · Circulation
  54. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta‐Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials
    Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, Paolo Chiodini, Katherine Esposito · 2019 · Journal of the American Heart Association
  55. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
    Emir M. Muzurović, Špela Volčanšek, Karin Zibar, Andrej Janež, Dimitri P. Mikhailidis, Manfredi Rizzo, Christos Socrates Mantzoros · 2022 · Journal of Cardiovascular Pharmacology and Therapeutics
  56. Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
    Silviu Marcel Stanciu, Emilia Rusu, Daniela Miricescu, Ana Cristina Radu, Bianca Axinia, Ana-Maria Vrabie, Ruxandra Florentina Ionescu, Mariana Jinga, Carmen Adella Sîrbu · 2023 · Metabolites
  57. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity
    Matthew M.Y. Lee, Nazim Ghouri, Anoop Misra, Yu Mi Kang, Martin K. Rutter, Hertzel C. Gerstein, Darren K. McGuire, Naveed A. Sattar · 2025 · Diabetes Care
  58. Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
    Guntram Schernthaner, Marie Helene Schernthaner-Reiter · 2018 · Diabetologia
  59. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
    David M. Williams, Hannah F Jones, Jeffrey Wayne Stephens · 2022 · Dove Medical Press (Taylor and Francis Group)
  60. Future glucose-lowering drugs for type 2 diabetes
    Clifford J. Bailey, Abd A. Tahrani, Anthony H Barnett · 2016 · The Lancet Diabetes & Endocrinology
  61. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
    Kumarathurai, Preman, Anholm, Christian, Larsen, Bjørn S., Olsen, Rasmus Huan, Madsbad, Sten, Kristiansen, Ole, Nielsen, Olav W., Haugaard, Steen B., Sajadieh, Ahmad · 2017 · Diabetes Care
  62. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data
    Evgenia Gourgari, Erin E. Wilhelm, Hamid Reza Hassanzadeh, Vanita R. Aroda, Ira Shoulson · 2017 · Journal of Diabetes and its Complications
  63. Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
    Matteo Monami, Ilaria Dicembrini, Edoardo Mannucci · 2016 · Acta Diabetologica
  64. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics
    Jennifer B. Green, Adrian F. Hernandez, Ralph B. D’Agostino, Christopher Bull Granger, Salim G. Janmohamed, Nigel P. Jones, Lawrence A. Leiter, Drusilla Noronha, Rachael Russell, Kristina N. Sigmon et al. · 2018 · American Heart Journal
  65. The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
    Jonathan D. Newman, Anish K. Vani, José O. Alemán, HOWARD S. WEINTRAUB, Jeffrey S. Berger, Arthur Z. Schwartzbard · 2018 · Journal of the American College of Cardiology
  66. Incretins in obesity and diabetes
    Chia, Chee W., Egan, Josephine M. · 2020 · Annals of the New York Academy of Sciences
  67. Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
    Nauck, Michael A., Jensen, Thomas Jon, Rosenkilde, Carina, Calanna, Salvatore, Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2018 · Diabetes Care
  68. Semaglutide: review and place in therapy for adults with type 2 diabetes
    Goldenberg, Ronald M., Steen, Oren · 2019 · Canadian Journal of Diabetes
  69. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
    Bart Staels · 2017 · The American Journal of Medicine
  70. New strategies to improve clinical outcomes for diabetic kidney disease
    Thomas M. Forst, Chantal Mathieu, Francesco Giorgino, David Collins. Wheeler, Νικόλαος Παπάνας, Roland Erich Schmieder, Atef Halabi, Oliver Schnell, Marina Streckbein, Katherine R. Tuttle · 2022 · BMC Medicine
  71. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
    Seminer, Allie, Mulihano, Alfredi, O’Brien, Clare, Krewer, Finn, Costello, Maria, Judge, Conor, O’Donnell, Martin, Reddin, Catriona · 2025 · JAMA Neurology
  72. Newer GLP-1 receptor agonists and obesity-diabetes
    Emily E. Brown, Daniel James Cuthbertson, John P.H. Wilding · 2018 · Peptides
  73. Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date
    Lavanya Athithan, Gaurav Singh Gulsin, Gerry Patrick McCann, Eylem Levelt · 2019 · World Journal of Diabetes
  74. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
    Rozalina G. McCoy, Holly K. Van Houten, Yihong Deng, Pinar Karaca‐Mandic, Joseph S. Ross, Víctor M. Montori, Nilay D. Shah · 2021 · JAMA Network Open
  75. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
    Lim, Lee-Ling, Chow, Elaine, Chan, Juliana C. N. · 2023 · Nature Reviews Endocrinology
  76. Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
    Erin D. Michos, Francisco Alejandro López-Jiménez, Martha Gulati · 2023 · Journal of the American Heart Association
  77. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
    David E. Kloecker, Melanie Jane Davies, Kamlesh Khunti, Francesco Zaccardi · 2020 · Annals of Internal Medicine
  78. Perspectives in GLP-1 Research: New Targets, New Receptors
    Giulia Cantini, Edoardo Mannucci, Michaela Luconi · 2016 · Trends in Endocrinology and Metabolism
  79. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Marian Sue Kirkman, Hussain Mahmud, Mary T. Korytkowski · 2018 · Endocrinology and Metabolism Clinics of North America
  80. Diabetic heart disease: A clinical update
    Jake Rajbhandari, Cornelius James Fernandez, Mayuri Agarwal, Beverly Xin Yi Yeap, Joseph M Pappachan · 2021 · World Journal of Diabetes
  81. Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis
    Ioannis Avgerinos, Theodoros Michailidis, Aris Liakos, Thomas Karagiannis, David Richard Matthews, Απόστολος Τσάπας, Eleni Bekiari · 2019 · Diabetes Obesity and Metabolism
  82. 2020 Clinical practice guidelines for Chronic heart failure
    Russian Society of Cardiology · 2020 · Russian Journal of Cardiology
  83. GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
    Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo · 2022 · Kidney Research and Clinical Practice
  84. Management of diabetes in older adults
    Giorgio Sesti, Raffaele Antonelli Incalzi, Enzo Bonora, Agostino Consoli, Andrea Giaccari, Stefania Maggi, Giuseppe Paolisso, Francesco Purrello, Gianluigi Vendemiale, Nicola Ferrara · 2017 · Nutrition Metabolism and Cardiovascular Diseases
  85. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
    Lyseng-Williamson, Katherine A. · 2019 · Clinical Drug Investigation
  86. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
  87. Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
    Steinberg, William M., Buse, John B., Ghorbani, Marie Louise Muus, Ørsted, David D., Nauck, Michael A., the LEADER Steering Committee, on behalf of the LEADER Trial Investigators · 2017 · Diabetes Care
  88. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie Mitchell Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew Jay Budoff, Javed Butler, David Z.I. Cherney et al. · 2024 · Metabolism
  89. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study
    Choi, Jin G., Winn, Aaron N., Skandari, M. Reza, Franco, Melissa I., Staab, Erin M., Alexander, Jason, Wan, Wen, Zhu, Mengqi, Huang, Elbert S., Philipson, Louis et al. · 2022 · Annals of Internal Medicine
  90. Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome
    Josephine Harrington, W. Schuyler Jones, Jacob Allen Udell, Karen L. Hannan, Deepak L. Bhatt, Stefan D. Anker, Mark Colquhoun Petrie, Ola Vedin, Javed Butler, Adrian F. Hernandez · 2022 · JACC Heart Failure
  91. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó, Rafael, Hernández, Cristina · 2017 · Diabetes
  92. Novel Diabetes Drugs and the Cardiovascular Specialist
    Naveed A. Sattar, Mark Colquhoun Petrie, Bernard Zinman, James L. Januzzi · 2017 · Journal of the American College of Cardiology
  93. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
    Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2020 · Nutrition Metabolism and Cardiovascular Diseases
  94. Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
    Giovana Fagundes Piccoli, Leonardo A Mesquita, Cinara Stein, Marina Meneses Aziz, Maira Zoldan, Nathália Abi Habib Degobi, Bernardo Frison Spiazzi, Gilberto L Lopes Junior, Verônica Colpani, Fernando Gerchman · 2020 · The Journal of Clinical Endocrinology & Metabolism
  95. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
    Anniek Frederike Lubberding, Simon Veedfald, Jonathan Samuel Achter, Sarah Dalgas Nissen, Luca Soattin, Andrea Sorrentino, Estefanía Torres-Vega, Benedikt M. Linz, Caroline Eggert Eggertsen, John F. Mulvey et al. · 2024 · Cardiovascular Research
  96. Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records
    Elisabetta Patorno, Chandrasekar Gopalakrishnan, Jessica Myers Franklin, Kimberly Goodnow Brodovicz, Elvira L Massó-González, Dorothee B. Bartels, Jun Liu, Sebastian Schneeweiß · 2017 · Diabetes Obesity and Metabolism
  97. Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality
    Valentina Milazzo, Nicola Cosentino, Stefano Genovese, Jeness Campodonico, Mario Mazza, Monica De Metrio, Giancarlo Marenzi · 2020 · Advances in experimental medicine and biology
  98. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis
    Bellastella, Giuseppe, Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2020 · Stroke
  99. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
    Paneni, Francesco, Lüscher, Thomas F. · 2017 · The American Journal of Cardiology
  100. Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
    Gillian L. Booth, Lorraine Lucille Lipscombe, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R. Shah, Scot H. Simpson et al. · 2016 · Canadian Journal of Diabetes